Glide Technologies received a subcontract extension for the advancement of an alternative delivery method for Pfenex’s recombinant Protective Antigen, Px563L-mrPA, using its solid dose formulation technology. This contract continuation is the result of the National Institute of Allergy and Infectious Diseases (NIAID) exercising its first contract option under its existing contract with Pfenex. “We are pleased with the early results and the development of this potential additional p...